Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Moodys
McKinsey
AstraZeneca
Dow

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

MS CONTIN Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Ms Contin, and when can generic versions of Ms Contin launch?

Ms Contin is a drug marketed by Purdue Pharma Lp and is included in one NDA.

The generic ingredient in MS CONTIN is morphine sulfate. There are twenty-three drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.

Drug patent expirations by year for MS CONTIN
Drug Prices for MS CONTIN

See drug prices for MS CONTIN

Drug Sales Revenue Trends for MS CONTIN

See drug sales revenues for MS CONTIN

Recent Clinical Trials for MS CONTIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Medical University InnsbruckPhase 2
National Institute of Nursing Research (NINR)Phase 4
Ranbaxy Inc.Phase 1

See all MS CONTIN clinical trials

Recent Litigation for MS CONTIN

Identify potential future generic entrants

District Court Litigation
Case NameDate
Purdue Pharma L.P. v. Alvogen Pine Brook LLC2015-08-05

See all MS CONTIN litigation

Pharmacology for MS CONTIN
Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Synonyms for MS CONTIN
(-)-(etorphine)
(-)-Morphine
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)Morphine sulfate
(1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7,9,11(18),15-tetraene-10,14-diol
(1S,5R,13R,14S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0;{1,13}.0;{5,17}.0;{7,18}]octadeca-7(18),8,10,15-tetraene-10,14-diol
(1S,5R,13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
(4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol
(5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6beta)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
(Morphine)
(morphine) 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
1325730-46-8
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
2-{4-[2,4-diamino-6-pteridinylmethyl(methyl)amino]phenylcarboxamido}pentanedioic acid(morphine)
3-(4-Hydroxy-phenyl)-1-propyl-piperidine-3-carboxylic acid ethyl ester
4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol ; HydroChloride
4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol ;sulphate salt(morphine)
4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol,sulfate(Morphinesulfate)
4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol((Morphine))
4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(morphine sulfate)
4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(morphine)
4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(Morphine)(HCl)
4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diolMorphine
4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol (morphine)
4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(Morphine)
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
47106-99-0
57-27-2
6-tert-Butyl-3-methyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine
6,11-Dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol(Morphine)
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol(morphine)
76I7G6D29C
8053-16-5
85201-37-2
863713-90-0
9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-
9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4alpha,5,7alpha,8-tetrahydro-12-methyl-
Aguettant
AKOS015966554
AN-23579
AN-23737
Astramorph PF
Avinza
BDBM50000092
BIDD:GT0147
BQJCRHHNABKAKU-KBQPJGBKSA-N
C01516
CCRIS 5762
CHEBI:17303
CHEMBL3978843
CHEMBL70
Cube juice
D-(-)-Morphine
D08233
DB00295
DEA No. 9300
DepoDur
Dimorf
Dinamorf
Dolcontin
Dreamer
DTXSID9023336
Dulcontin
Duramorph
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
Epitope ID:116646
GTPL1627
Hard stuff
Hocus
HSDB 2134
Infumorph
Kadian
l-Morphine
LS-91748
M-Eslon
M.O.S
Meconium
methyl[?]diol
MOI
Morfina
Morfina [Italian]
Morfina Dosa (TN)
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
Morphinan-3,6-alpha-diol, 7,8-didehydro-4,5-alpha-epoxy-17-methyl-
Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5..alpha.,6.alpha.)-
Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5alpha,6alpha)-
Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5alpha,6alpha)-
morphine
Morphine (BAN)
Morphine [BAN]
Morphine 0.1 mg/ml in Methanol
Morphine 1.0 mg/ml in Methanol
Morphine Anhydrate
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
MORPHINE SULFATE
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
Morphine;4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Emma
MS/L
MS/S
Mscontin, Oramorph
MSIR
Nepenthe
NSC11441
OMS Concentrate
Oramorph
Oramorph SR
Ospalivina
Rescudose
RMS
RMS Uniserts
Roxanol
Roxanol 100
Roxanol UD
SCHEMBL2997
SDZ 202-250
SDZ202-250
Sevredol
Statex Drops
Statex SR
Substitol (TN)
UNII-1M5VY6ITRT component BQJCRHHNABKAKU-KBQPJGBKSA-N
UNII-76I7G6D29C
Unkie
ZINC3812983

US Patents and Regulatory Information for MS CONTIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Purdue Pharma Lp MS CONTIN morphine sulfate TABLET, EXTENDED RELEASE;ORAL 019516-003 Sep 12, 1989 AB RX Yes No   Start Trial   Start Trial   Start Trial
Purdue Pharma Lp MS CONTIN morphine sulfate TABLET, EXTENDED RELEASE;ORAL 019516-004 Jan 16, 1990 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Purdue Pharma Lp MS CONTIN morphine sulfate TABLET, EXTENDED RELEASE;ORAL 019516-001 May 29, 1987 AB RX Yes No   Start Trial   Start Trial   Start Trial
Purdue Pharma Lp MS CONTIN morphine sulfate TABLET, EXTENDED RELEASE;ORAL 019516-002 Apr 8, 1988 AB RX Yes No   Start Trial   Start Trial   Start Trial
Purdue Pharma Lp MS CONTIN morphine sulfate TABLET, EXTENDED RELEASE;ORAL 019516-005 Nov 8, 1993 AB RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for MS CONTIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Purdue Pharma Lp MS CONTIN morphine sulfate TABLET, EXTENDED RELEASE;ORAL 019516-003 Sep 12, 1989   Start Trial   Start Trial
Purdue Pharma Lp MS CONTIN morphine sulfate TABLET, EXTENDED RELEASE;ORAL 019516-005 Nov 8, 1993   Start Trial   Start Trial
Purdue Pharma Lp MS CONTIN morphine sulfate TABLET, EXTENDED RELEASE;ORAL 019516-004 Jan 16, 1990   Start Trial   Start Trial
Purdue Pharma Lp MS CONTIN morphine sulfate TABLET, EXTENDED RELEASE;ORAL 019516-002 Apr 8, 1988   Start Trial   Start Trial
Purdue Pharma Lp MS CONTIN morphine sulfate TABLET, EXTENDED RELEASE;ORAL 019516-001 May 29, 1987   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Harvard Business School
McKinsey
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.